◆英語タイトル:Antibe Therapeutics Inc (ATE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013105
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月27日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Antibe Therapeutics Inc (Antibe) is a biotechnology company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercialize novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen derivative for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis; ATB-352 for gout, dysmenorrhea, dental pain, post-surgical pain, and ATB-340 for chronic prevention of cardiovascular disease and cancer chemoprevention. Antibe also offers regenerative medical devices, which include CGX-227, CGX-443 and CGX-276 which are indicated for oral and maxillofacial surgery. The company distributes its products across Europe, the Americas, the Middle East and Asia.Antibe is headquartered in Toronto, Ontario, Canada.
Antibe Therapeutics Inc (ATE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Antibe Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Laboratories Acbel Enters into Licensing Agreement with Antibe Therapeutics for ATB-346 11
Knight Therapeutics Enters into Licensing Agreement with Antibe Therapeutics 12
Equity Offering 13
Antibe Therapeutics Raises USD3 Million in Public Offering of Units 13
Antibe Therapeutics Raises USD2 Million in Private Placement of Units 15
Antibe Therapeutics Raises USD0.4 Million in Second and Final Tranche of Private Placement of Units 16
Antibe Therapeutics Raises USD0.8 Million in First Tranche of Private Placement of Units 17
Antibe Therapeutics Raises USD0.5 Million in Private Placement of Units 19
Antibe Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$3.5 Million 20
Antibe Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.2 Million 21
Antibe Therapeutics Completes IPO For US$3 Million 22
Antibe Therapeutics Completes Private Placement Of Common Stock For US$0.2 Million 24
Debt Offering 25
Antibe Therapeutics Raises USD0.3 Million in First Tranche of Private Placement of 10% Debentures Due 2018 25
Antibe Therapeutics Raises USD1.4 Million in First Tranche of Private Placement of 10% Debentures 26
Antibe Therapeutics Inc – Key Competitors 27
Antibe Therapeutics Inc – Key Employees 28
Antibe Therapeutics Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 29, 2017: Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results 30
Mar 01, 2017: Antibe Therapeutics Reports Q3 2017 Interim Financial and Operating Results 31
Nov 29, 2016: Antibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results 32
Corporate Communications 33
Jul 19, 2016: Antibe Therapeutics Announces the Appointment of New Board Member 33
Other Significant Developments 34
Aug 29, 2016: Antibe Therapeutics Reports Q1 2017 Interim Financial and Operating Results 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35
List of Tables
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Antibe Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Antibe Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Antibe Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Laboratories Acbel Enters into Licensing Agreement with Antibe Therapeutics for ATB-346 11
Knight Therapeutics Enters into Licensing Agreement with Antibe Therapeutics 12
Antibe Therapeutics Raises USD3 Million in Public Offering of Units 13
Antibe Therapeutics Raises USD2 Million in Private Placement of Units 15
Antibe Therapeutics Raises USD0.4 Million in Second and Final Tranche of Private Placement of Units 16
Antibe Therapeutics Raises USD0.8 Million in First Tranche of Private Placement of Units 17
Antibe Therapeutics Raises USD0.5 Million in Private Placement of Units 19
Antibe Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$3.5 Million 20
Antibe Therapeutics Completes Second Tranche Of Private Placement Of Units For US$1.2 Million 21
Antibe Therapeutics Completes IPO For US$3 Million 22
Antibe Therapeutics Completes Private Placement Of Common Stock For US$0.2 Million 24
Antibe Therapeutics Raises USD0.3 Million in First Tranche of Private Placement of 10% Debentures Due 2018 25
Antibe Therapeutics Raises USD1.4 Million in First Tranche of Private Placement of 10% Debentures 26
Antibe Therapeutics Inc, Key Competitors 27
Antibe Therapeutics Inc, Key Employees 28
Antibe Therapeutics Inc, Subsidiaries 29